News

CAP-003, a gene therapy for Parkinson’s disease associated with GBA mutations, has been cleared by the U.S. Food and Drug Administration (FDA) for testing in clinical trials. These mutations are the most common genetic risk factor for Parkinson’s. With this FDA clearance, developer Capsida Biotherapeutics plans to launch a…

Parkinson’s disease patients in a pilot study testing the effects of equine-associated therapy report that they enjoy working with horses, while researchers say they hope results from the program will provide evidence of its benefits. “We hope to show there is effectiveness in this type of treatment to apply…

Stimulating nerve cells in a region of the brain involved in processing sound and emotions may help ease motor symptoms such as those caused by Parkinson’s disease, without unwanted side effects on emotional response, according to a study in rats. While it’s still early to understand if these…

Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying oral treatment for people with Parkinson’s disease and Gaucher disease. CSM-101 is a first-in-class small molecule designed to activate the calcium channel TRPML1, a key regulator of lysosomal function and autophagy, a process in which cells deliver…

People with Parkinson’s disease who have mild cognitive changes before deep brain stimulation (DBS) are not more likely to develop dementia later in life than those whose cognitive function was normal before the surgery, a Danish study has found. Instead, the researchers observed that dementia was more likely…

Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics and daily symptoms are connected in people with Parkinson’s disease, with the aim of speeding diagnosis, improving clinical trial design, and supporting the development of more targeted treatments. The…

Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments for Parkinson’s disease — assessing whether any of them can engage with their intended targets in the brain. The results are expected to help decide if these treatments should…

The first patient has been dosed in a pivotal Phase 2/3 clinical trial testing BHV-8000, a brain-penetrant oral small molecule that Biohaven Therapeutics is developing as a disease-modifying therapy for neuroinflammatory conditions, including Parkinson’s disease. The clinical trial (NCT06976268) is evaluating the effectiveness and safety of BHV-8000…

Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently…

Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending…